Genasense oblimersen regulatory update

GNTA withdrew its NDA for Genasense to treat advanced melanoma. The move follows a 13-3 vote by an FDA panel that the results of GNTA's Phase III trial of Genasense plus dacarbazine (DTIC) vs. DTIC al...